SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.
Raymond A Plodkowski(University of California San Diego), Quang T. Nguyen, Bradley Kramer(VA Sierra Nevada Health Care System), Heather M. Huribal(VA Sierra Nevada Health Care System), Megan E. McGarvey(VA Sierra Nevada Health Care System), Keith Reisinger‐Kindle(VA Sierra Nevada Health Care System), Mordecai Solomon(VA Sierra Nevada Health Care System)
PubMed
October 1, 2015
Cited by 16
Related Papers
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
|Diabetes Care|2013|494